The study suggests that pediatric low-grade gliomas driven by genetic rearrangements tend to be diagnosed earlier and have better outcomes than those driven by SNVs.
After a study showed that patients who received guidance from Perthera's tumor board lived longer than those who didn't, the company wants to make its technology more accessible.
Paired tumor/germline analysis is not routinely done in cancer care, but some labs are starting to report incidental germline findings alongside patient's tumor profiles.
Members of a large, international consortium tapped into whole-genome sequences from nearly 2,700 tumors to explore coding and non-coding variants contributing to cancer.
Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.
The approval of its Omics Core assay for tumor-normal mutational profiling opens the door for payor reimbursement, which is key to reaching profitability, NantHealth said.
Exome sequences from dozens of cervical cancer tumor or primary cell line samples revealed recurrent alterations affecting ERBB2/HER2 and PIK3CA pathways.
Tempus Labs researchers said they could match more than 40 percent of patients to a targeted treatment and 77 percent of patients to a relevant clinical trial.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.
